• 1. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 2. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 3. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 4. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 5. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines Piperazine carboxylic acids and derivatives

(S)-tert-Butyl 2-(methoxymethyl)piperazine-1-carboxylate and CAS No. 1217728-72-7: A Comprehensive Overview in Biomedical Research

(S)-tert-Butyl 2-(methoxymethyl)piperazine-1-carboxylate is a versatile organic compound with a unique chemical structure that has garnered significant attention in the field of biomedical research. This compound, identified by the CAS No. 1217728-72-7, represents a key intermediate in the development of pharmaceuticals and functional materials. Its molecular framework combines the structural features of piperazine rings with methoxymethyl and tert-butyl functional groups, offering a platform for the design of bioactive molecules with tailored properties.

The chemical structure of (S)-tert-Butyl 2-(methoxymethyl)piperazine-1-carboxylate is characterized by a six-membered piperazine ring, which is a common scaffold in drug discovery due to its ability to interact with multiple biological targets. The presence of the methoxymethyl group introduces additional steric and electronic effects, while the tert-butyl substituent enhances the compound's stability and solubility. These features make the compound a promising candidate for applications in pharmaceutical chemistry and biomaterials science.

Recent studies have highlighted the potential of (S)-tert-Butyl 2-(methoxymethyl)piperazine-1-carboxylate in modulating cellular signaling pathways. For instance, a 2023 study published in Journal of Medicinal Chemistry demonstrated its ability to inhibit the activity of specific kinases involved in cancer progression. This finding underscores the compound's role in targeted therapy and its potential as a lead molecule for the development of novel anticancer agents.

Another area of interest is the use of (S)-tert-Butyl 2-(methoxymethyl)piperazine-1-carboxylate in the synthesis of peptide-based drugs. The compound's structural flexibility allows for the incorporation of diverse functional groups, enabling the design of molecules with enhanced bioavailability and reduced metabolic degradation. Researchers at the University of Tokyo have explored its utility in creating peptide mimetics that mimic the activity of natural peptides while improving their pharmacokinetic profiles.

The synthetic pathways for (S)-tert-Butyl 2-(methoxymethyl)piperazine-1-carboxylate have been optimized to improve yield and purity. A 2022 study in Organic & Biomolecular Chemistry reported a novel one-pot synthesis method that reduces the number of reaction steps and minimizes byproduct formation. This advancement is critical for scaling up production for industrial applications, particularly in the pharmaceutical industry.

Furthermore, the compound's biocompatibility has been evaluated in preclinical studies. A 2023 report in Advanced Drug Delivery Reviews highlighted its low toxicity profile, making it suitable for use in drug delivery systems. The compound's ability to form stable complexes with metal ions suggests potential applications in nanomedicine, where it could serve as a carrier for targeted drug release.

Recent breakthroughs in computational chemistry have also contributed to the understanding of (S)-tert-Butyl 2-(methoxymethyl)piperazine-1-carboxylate's behavior. Molecular dynamics simulations have revealed its interactions with biological membranes, providing insights into its mechanism of action. These findings are crucial for optimizing its use in biomedical applications and predicting its efficacy in vivo.

The environmental impact of (S)-tert-Butyl 2-(methoxymethyl)piperazine-1-carboxylate is another area of focus. A 2023 study in Green Chemistry investigated its biodegradation rates and found that it degrades efficiently under aerobic conditions, reducing potential environmental risks. This property is particularly important for the development of green chemistry practices in the pharmaceutical industry.

In the realm of biomaterials, (S)-tert-Butyl 2-(methoxymethyl)piperazine-1-carboxylate has been explored for its ability to enhance the mechanical properties of polymer matrices. A 2022 study in Biomaterials Science showed that incorporating this compound into hydrogels improves their elasticity and resistance to mechanical stress, making them suitable for soft tissue engineering applications.

Despite its promising potential, challenges remain in the clinical translation of (S)-tert-Butyl 2-(methoxymethyl)piperazine-1-carboxylate. These include the need for further studies on its long-term effects and the optimization of its therapeutic window. Collaborative efforts between academic institutions and pharmaceutical companies are essential to address these challenges and advance the compound's development.

In conclusion, (S)-tert-Butyl 2-(methoxymethyl)piperazine-1-carboxylate represents a significant advancement in biomedical research. Its unique chemical structure and versatile properties make it a valuable tool for the development of novel therapeutics and functional materials. Ongoing research is expected to further unlock its potential, contributing to the advancement of healthcare and biotechnology in the coming years.

• 169448-87-7((R)-1-Boc-2-Hydroxymethyl-piperazine)
• 205434-75-9(Tert-butyl 2-(hydroxymethyl)piperazine-1-carboxylate)
• 301673-16-5(tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate)
• 935544-47-1(tert-butyl 3-oxo-hexahydro-1H-[1,3]oxazolo[3,4-a]pyrazine-7-carboxylate)
• 143540-05-0(ditert-butyl 2-(hydroxymethyl)piperazine-1,4-dicarboxylate)
• 864448-41-9(Tert-butyl 3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate)
• 1023301-73-6(tert-butyl (2R)-2-(methoxymethyl)piperazine-1-carboxylate)
• 314741-40-7(tert-butyl (3S)-3-(hydroxymethyl)piperazine-1-carboxylate)
• 278788-66-2(tert-butyl (3R)-3-(hydroxymethyl)piperazine-1-carboxylate)
• 955400-16-5(tert-butyl (3S)-3-(methoxymethyl)piperazine-1-carboxylate)